Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine for Prevention of Leukemia in Infants with Transient Abnormal Myelopoiesis (TAM-25)
jRCTs041250149Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of azacitidine in transient leukemia (TAM) and acute myeloid leukemia (AML), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Cumulative incidence of ML-DS at two years after TAM diagnosis in FCM-MRD-positive patients. Started Jan 2026; status: recruiting.
02
Drugs
azacitidine
03
Conditions
transient leukemia (TAM)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCTs041250149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250149.